[
    [
        {
            "time": "2018-01-03",
            "original_text": "Yacktman Focused Fund's Top 5 Sells in the 4th Quarter",
            "features": {
                "keywords": [
                    "Yacktman",
                    "Focused",
                    "Fund",
                    "Top",
                    "Sells",
                    "4th",
                    "Quarter"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 3,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "Judge Cuts $8 Billion J&J Jury Award to $6 Million",
            "features": {
                "keywords": [
                    "Judge",
                    "Cuts",
                    "$8",
                    "Billion",
                    "J&J",
                    "Jury",
                    "Award",
                    "$6",
                    "Million"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "Q4 Earnings Season Showing Revenue Momentum",
            "features": {
                "keywords": [
                    "Q4",
                    "Earnings",
                    "Season",
                    "Revenue",
                    "Momentum"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "Judge slashes $8 bln Risperdal award against Johnson & Johnson to $6.8 mln",
            "features": {
                "keywords": [
                    "Judge",
                    "slashes",
                    "$8",
                    "bln",
                    "Risperdal",
                    "award",
                    "against",
                    "Johnson",
                    "&",
                    "Johnson",
                    "$6.8",
                    "mln"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-07",
            "original_text": "The Zacks Analyst Blog Highlights: AAPL, JNJ, PG and AXP",
            "features": {
                "keywords": [
                    "Zacks",
                    "Analyst",
                    "Blog",
                    "Highlights",
                    "AAPL",
                    "JNJ",
                    "PG",
                    "AXP"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "technology",
                    "healthcare",
                    "consumer goods",
                    "finance"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-08",
            "original_text": "The Zacks Analyst Blog Highlights: JPM, JNJ, CVX and PG",
            "features": {
                "keywords": [
                    "Zacks",
                    "Analyst",
                    "Blog",
                    "Highlights",
                    "JPM",
                    "JNJ",
                    "CVX",
                    "PG"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance",
                    "healthcare",
                    "energy",
                    "consumer goods"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-09",
            "original_text": "Is Johnson & Johnson (JNJ) A Good Pick for Value Investors?",
            "features": {
                "keywords": [
                    "Johnson",
                    "&",
                    "Johnson",
                    "(JNJ)",
                    "Good",
                    "Pick",
                    "Value",
                    "Investors"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-10",
            "original_text": "Will J&J (JNJ) Roll Out Pharma Q4 Earnings With a Beat?",
            "features": {
                "keywords": [
                    "J&J",
                    "(JNJ)",
                    "Roll",
                    "Out",
                    "Pharma",
                    "Q4",
                    "Earnings",
                    "Beat"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-11",
            "original_text": "Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates",
            "features": {
                "keywords": [
                    "Pharma",
                    "Stock",
                    "Roundup",
                    "LLY",
                    "Dermira",
                    "Buyout",
                    "Offer",
                    "Pipeline",
                    "Regulatory",
                    "Updates"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]